ArticleTranslational andrology and urology2025
Testosterone therapy in patients with locoregional prostate cancer treated with prior androgen deprivation therapy and radiation: a retrospective single center review.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review of safety and efficacy.International journal of impotence research · 2025Review
- Real-world effectiveness of rezvilutamide plus androgen deprivation therapy in patients with low-volume, metastatic hormone-sensitive prostate cancer: a retrospective multicenter study.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In locoregional prostate cancer (PC), androgen deprivation therapy (ADT) is combined with radiation therapy (RT) for 4-24 months. Post-ADT, some men remain hypogonadal. Sparse data exist regarding the safety and prostate cancer recurrence risk with testosterone therapy (TTh) after prior ADT/RT. The aim of the study is to share Lahey Hospital & Medical Center's experience with patients receiving TTh after previous treatment with ADT and RT, with the goal of contributing to the existing literature on TTh safety in this population to set the stage for a prospective trial. Methods: We abstracted clinical data in patients with stage I-IVA PC, treated with ADT and RT and subsequently received TTh between 2014-2023. The co-primary endpoints were change in prostate-specific antigen (PSA) and incidence of PC recurrence. Results: Twenty-one patients met criteria. Grade groups (GG) results included: GG1, n=2; GG2, n=2; GG3, n=8; GG4, n=2; and GG5, n=7. American Joint Committee on Cancer (AJCC) stages were: I, n=2; II, n=7; III, n=7; IVA, n=5. Median interval from RT to TTh was 19 months. Prior to TTh, median testosterone was 38 ng/dL. Median follow-up was 15 months. TTh was ongoing in 15 (71.4%) patients and discontinued in 6 (28.6%). Reasons for discontinuation included testosterone recovery (n=1), hospice (not PC-related) (n=2), no perceived benefit (n=2), and physician concern for PSA rise (n=1). After TTh, median testosterone level was 318 ng/dL. Mean PSA pre- and post-TTh were 0.086 and 0.193 ng/dL (P=0.008). No patients experienced PC recurrence. One patient showed PSA bounce without recurrence. Conclusions: In men with locoregional PC who remained hypogonadal after prior ADT and RT, we found that TTh was not associated with a clinically significant rise in mean PSA and no cases of PC recurrence were documented. These findings support the case for a prospective trial in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.